Streetbeat News

STTK

Shattuck Labs, Inc.

https://www.shattucklabs.com

Industry

Biotechnology

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Open

1.40

Mkt cap

59M

Volume

218K

High

1.45

P/E Ratio

-0.67

52-wk high

11.76

Low

1.23

Div yield

N/A

52-wk low

1.07

Citigroup analyst Yigal Nochomovitz has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Neutral and reduced the price target from $8 to $2.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:40 pm

Needham analyst Gil Blum has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Hold, while maintaining a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:41 am

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Notable gainers included Nuwellis, Sagimet Biosciences, and Opthea, while Gritstone Bio and Applied DNA Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 4:31 pm

Shattuck Labs (NASDAQ:STTK) is reorganizing its pipeline, discontinuing its SL-172154 cancer program, and laying off 40% of its workforce. The company will focus on developing SL-325 for inflammatory bowel disease. Despite the changes, Shattuck's cash reserves are expected to fund operations until 2027. The stock fell 42.4% following the announcement.

Portfolio Pulse from Vandana Singh

October 01, 2024 | 4:26 pm

HC Wainwright & Co. has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Neutral, as per analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:16 pm

Shattuck Labs shares experienced a trading halt due to a circuit breaker triggered by a rapid price movement. Despite this, the stock is currently down by 39.3%.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:57 pm

Shattuck Labs shares fell after announcing the discontinuation of its SL-172154 clinical program due to modest results. The company will focus on developing SL-325 for inflammatory bowel disease, with an IND filing expected in Q3 2025. Restructuring is expected to extend cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 12:13 pm

The article highlights the pre-market movements of various healthcare stocks on Tuesday. Notable gainers include Silexion Therapeutics, Adagio Medical Holdings, and Chromocell Therapeutics, while significant losers include Shattuck Labs, IGM Biosciences, and Applied DNA Sciences.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 12:07 pm

Shattuck Labs is discontinuing the development of SL-172154 due to modest clinical results and will focus on SL-325 for inflammatory bowel disease. This restructuring is expected to extend their cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 10:34 am

Shattuck Labs (NASDAQ:STTK) has received mixed analyst ratings over the past three months, with a notable decrease in the average price target by 18.18%. Analysts have maintained a 'Buy' rating but adjusted price targets, reflecting a cautious outlook. The company, a clinical-stage biotech firm, has shown significant revenue growth but faces challenges with negative net margins and ROA.

Portfolio Pulse from Benzinga Insights

August 27, 2024 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.